摘要
目的 评价泰索帝 (docetaxel)单药治疗晚期非小细胞肺癌的客观有效率及毒性。方法 使用泰索帝单药治疗晚期非小细胞肺癌患者 15例 ,其中男性 10例 ,女性 5例。初治 11例 ,复治 4例。Ⅲ期患者 7例 ,Ⅳ期患者 8例。给予泰索帝 75～ 10 0mg/m2 。在给药前 1天开始口服地塞米松 7.5mg ,每天 2次 ,连续 5天。 结果 15例患者均完成 2个疗程以上的化疗。 3例患者达到部分缓解 ,6例患者病灶稳定 ,6例病情进展。总有效率为 2 0 .0 %。主要不良反应为骨髓抑制。 4例患者因白细胞下降导致感染发热。有 1例患者发生Ⅲ度过敏反应。其他不良作用包括脱发、肌肉酸痛、周围神经麻痹、面部潮红、液体潴留。结论 泰索帝75～ 10 0mg/m2 单药治疗非小细胞肺癌单药的有效率为 2 0 .0 % ,该药主要的不良作用是骨髓抑制。
Objective To evaluate the objective response and toxicity of single agent Docetaxel in the treatment of non small cell lung cancer.Methods 15 patients were included in this clinical trail(10 male and 5 female) 4 patients had received chemotherapy before,11 cases were previously untreated.Docetaxel was administered 75 mg～100 mg/m 2 by Ⅳ infusion,with a 5 day pre medication of corticosteroids to reduce the incidence of severe fluid retention and hypersensitivity.Results All patients had at least tow cycles of chemotherapy.There were 3 PR,6 NC and 6 PD.The response rate was 20%.Main side effect was bone marrow suppression.4 patients had neutropenia febrile and recovered after treatment.The grade Ⅲ of hypersensitivity was observed in 1 patient.The other side effects were alopecia,myalgia,peripheral nerve paralysis and fluid retention.Conclusion Docetaxel is an effective drug in the treatment of non small cell lung cancer.The main side effect was bone marrow suppression.
出处
《实用癌症杂志》
2000年第4期420-422,共3页
The Practical Journal of Cancer
关键词
非小细胞肺癌
泰索帝
药物疗法
Non small cell lung cancer
Docetaxel
Chemotherapy
